{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-099169","form_type":"8-K","ticker":"ANTX","cik":"0001880438","company_name":"AN2 Therapeutics, Inc.","filed_at":"2026-03-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.664049+00:00","generated_at":"2026-05-15T16:59:43.738830+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AN2 Therapeutics announces $40M private placement of common stock and pre-funded warrants","bullets":["Gross proceeds ~$40M from sale of 8.25M shares at $2.85/share and 5.79M pre-funded warrants at $2.84999/warrant.","Investors include Coastlands Capital, Commodore Capital, Vivo Capital; Leerink Partners as placement agent.","Pre-funded warrants have $0.00001 exercise price, exercisable immediately, subject to 9.99% beneficial ownership blocker.","Closing expected March 10, 2026; resale registration statement to be filed within 30 days after closing.","Net proceeds for general corporate purposes and working capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-099169","json":"https://secwatch.observer/filing/0001193125-26-099169.json","markdown":"https://secwatch.observer/filing/0001193125-26-099169.md","text":"https://secwatch.observer/filing/0001193125-26-099169.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526099169/0001193125-26-099169-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526099169/d14366d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T16:59:43.738830+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bdd4f4ee7ba09af54d941f11a7c235677f8edc5c","claim":"AN2 Therapeutics, Inc. entered into Securities Purchase Agreement with certain investors valued at approximately $40 million (effective 2026-03-08).","evidence_excerpt":"On March 8, 2026, AN2 Therapeutics, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain investors (the “Purchasers”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1880438/000119312526099169/0001193125-26-099169-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain investors"},{"label":"Value","value":"approximately $40 million"},{"label":"Effective","value":"2026-03-08"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}